問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Veterans General Hospital

List

2394Cases

2020-10-15 - 2027-09-01

Phase III

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy (DESTINY-Breast05)

  • Condition/Disease

    HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast

  • Test Drug

    Trastuzumab deruxtecan (T-DXd; DS-8201a)

Participate Sites
13Sites

Recruiting13Sites

2019-10-01 - 2021-06-30

Phase II

A Phase IIa, Double-Blind, Single Dose, Randomized, Placebo-ControlledStudy to Evaluate the Safety, Tolerability, and Potential Efficacy of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS)

  • Condition/Disease

    Acute Ischemic Stroke

  • Test Drug

    LT3001 drug product

Participate Sites
6Sites

Recruiting4Sites

Study ended2Sites

趙雅琴
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2020-08-14 - 2027-07-24

Phase III

A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  • Condition/Disease

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    DEBIO 1143

Participate Sites
10Sites

Recruiting8Sites

Terminated2Sites

2020-06-01 - 2026-10-30

Phase III

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy

  • Condition/Disease

    biliary atresia

  • Test Drug

    Odevixibat (A4250)

Participate Sites
2Sites

Recruiting2Sites

2020-07-31 - 2021-12-07

Phase II

Randomized, double-blind, placebo-controlled trial of the safety, tolerability, and efficacy of RV521 in the treatment of adult subjects who have undergone hematopoietic cell transplantation (HCT) with a documented upper respiratory tract infection (URTI) with respiratory syncytial virus (RSV).

  • Condition/Disease

    respiratory syncytial virus

  • Test Drug

    RV521

Participate Sites
5Sites

Recruiting5Sites

2018-07-30 - 2022-08-13

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

王鵬惠
Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2018-06-04 - 2020-01-19

Phase III

A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-1)

  • Condition/Disease

    Age-Related Macular Degeneration (AMD)

  • Test Drug

    Conbercept

Participate Sites
5Sites

Recruiting5Sites

2018-04-20 - 2019-03-26

Phase II

A Phase 2A, Single Arm, Multicentre, Study of Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Who Progressed on at Least 1 Line of Systemic Therapy

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    varlitinib

Participate Sites
3Sites

Terminated3Sites

2020-05-18 - 2023-12-31

Others

A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001)

  • Condition/Disease

    Advanced Solid Tumors、non–small-cell lung cancer、squamous cell carcinoma of the head and neck、squamous tumor agnostic、hepatocellular carcinoma and small-cell lung cancer

  • Test Drug

    ALKS 4230

Participate Sites
6Sites

Recruiting6Sites

2014-04-30 - 2017-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

1 203 204 205 206 207 240
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB